Volume 74, Issue 1, Pages (July 2018)

Slides:

Advertisements

Similar presentations

Volume 69, Issue 5, Pages (May 2016)

Advertisements

Volume 61, Issue 5, Pages (May 2012)

Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial) M. Yoshida, K. Muro, A. Tsuji,

Metastatic Castration-Resistant Prostate Cancer: Two Case Reports of Dramatic Response with Abiraterone Acetate in Patients Heavily Pretreated with Chemotherapy.

Volume 57, Issue 1, Pages (January 2010)

Volume 50, Issue 1, Pages (July 2006)

Volume 52, Issue 1, Pages (July 2007)

Bone Scan Index as an Imaging Biomarker in Metastatic Castration-resistant Prostate Cancer: A Multicentre Study Based on Patients Treated with Abiraterone.

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 27, Issue 4, Pages (December 2016)

Testosterone Therapy in Men With Prostate Cancer

Volume 69, Issue 5, Pages (May 2016)

Volume 68, Issue 6, Pages e129-e131 (December 2015)

Volume 60, Issue 2, Pages (August 2011)

Volume 68, Issue 4, Pages (October 2015)

Volume 66, Issue 5, Pages (November 2014)

Volume 53, Issue 5, Pages (May 2008)

Control of Prostate Cancer by Transrectal HIFU in 227 Patients

Volume 69, Issue 5, Pages (May 2016)

Prostate Cancer Epidemic in Sight?

Volume 71, Issue 2, Pages (February 2017)

Treatment of Advanced and Metastatic Renal Cancer: A Revolution?

Volume 68, Issue 4, Pages (October 2015)

Volume 63, Issue 2, Pages (February 2013)

Volume 65, Issue 5, Pages (May 2014)

Tumour Grade, Treatment, and Relative Survival in a Population-based Cohort of Men with Potentially Curable Prostate Cancer Sam Ladjevardi, Gabriel Sandblom,

Volume 54, Issue 4, Pages (October 2008)

Elizabeth K. Bancroft, Rosalind A. Eeles

Volume 71, Issue 1, Pages 1-3 (January 2017)

Volume 70, Issue 4, Pages (October 2016)

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Prostate Cancer Detection: A View of the Future

Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance Adam B. Weiner, Ruth Etzioni, Scott E. Eggener

Volume 56, Issue 2, Pages (August 2009)

Volume 66, Issue 5, Pages (November 2014)

Volume 70, Issue 5, Pages (November 2016)

Laurent Boccon-Gibod European Urology Supplements

Prostate Cancer Epidemic in Sight?

Volume 65, Issue 2, Pages (February 2014)

Volume 61, Issue 5, Pages (May 2012)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 72, Issue 1, Pages (July 2017)

Volume 66, Issue 2, Pages (August 2014)

Volume 58, Issue 1, Pages 1-7 (July 2010)

Long-term Cancer-specific Survival in Patients with High-risk, Non–muscle-invasive Bladder Cancer and Tumour Progression: A Systematic Review Sven van.

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia

Volume 74, Issue 2, Pages (August 2018)

Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 Trial

Volume 50, Issue 5, Pages (November 2006)

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Volume 71, Issue 5, Pages (May 2017)

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Volume 59, Issue 4, Pages (April 2011)

Volume 70, Issue 1, Pages (July 2016)

Challenges and Opportunities in Hormone-Resistant Prostate Cancer

Volume 71, Issue 4, Pages (April 2017)

Jonathan S. Brajtbord, Michael S. Leapman, Matthew R. Cooperberg

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

Volume 69, Issue 5, Pages (May 2016)

European Urology Oncology

European Urology Oncology

Edith Canby-Hagino, Javier Hernandez, Timothy C. Brand, Ian Thompson

Volume 53, Issue 2, Pages (February 2008)

European Urology Oncology

Volume 54, Issue 3, Pages (September 2008)

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Volume 54, Issue 1, Pages (July 2008)

Volume 51, Issue 5, Pages (May 2007)

Presentation transcript:

Volume 74, Issue 1, Pages 17-23 (July 2018) The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score Kurt Miller, Joan Carles, Jürgen E. Gschwend, Hendrik Van Poppel, Joris Diels, Sabine D. Brookman-May European Urology Volume 74, Issue 1, Pages 17-23 (July 2018) DOI: 10.1016/j.eururo.2017.08.035 Copyright © 2017 European Association of Urology Terms and Conditions

Fig. 1 CONSORT study flow diagram. CONSORT=Consolidated Standards of Reporting Trials; ITT=intention to treat. European Urology 2018 74, 17-23DOI: (10.1016/j.eururo.2017.08.035) Copyright © 2017 European Association of Urology Terms and Conditions

Fig. 2 Kaplan–Meier analysis of time-to-event end points with abiraterone acetate plus prednisone and prednisone: (A) overall survival; (B) radiographic progression-free survival. (C) time to chemotherapy; and (D) time to opiate use. AA=abiraterone acetate; P=prednisone. European Urology 2018 74, 17-23DOI: (10.1016/j.eururo.2017.08.035) Copyright © 2017 European Association of Urology Terms and Conditions